Literature DB >> 23275077

Lipoxygenase products in the urine correlate with renal function and body temperature but not with acute transplant rejection.

Stephan W Reinhold1, Thomas Scherl, Benjamin Stölcker, Tobias Bergler, Ute Hoffmann, Christian Weingart, Miriam C Banas, Dmitrij Kollins, Martin C Kammerl, Bernd Krüger, Bernhard Kaess, Bernhard K Krämer, Bernhard Banas.   

Abstract

Acute transplant rejection is the leading cause of graft loss in the first months after kidney transplantation. Lipoxygenase products mediate pro- and anti-inflammatory actions and thus we aimed to correlate the histological reports of renal transplant biopsies with urinary lipoxygenase products concentrations to evaluate their role as a diagnostic marker. This study included a total of 34 kidney transplant recipients: 17 with an acute transplant rejection and 17 controls. LTE4, LTB4, 12-HETE and 15-HETE concentrations were measured by enzyme immunoassay. Urinary lipoxygenase product concentrations were not significantly changed during an acute allograft rejection. Nevertheless, LTB4 concentrations correlated significantly with the body temperature (P ≤ 0.05) 3 months after transplantation, and 12- and 15-HETE concentrations correlated significantly with renal function (P ≤ 0.05) 2 weeks after transplantation. In conclusion, our data show a correlation for LTB4 with the body temperature 3 months after transplantation and urinary 12- and 15-HETE concentrations correlate positively with elevated serum creatinine concentrations but do not predict acute allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23275077     DOI: 10.1007/s11745-012-3751-5

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  51 in total

1.  Lipoxygenase-derived hydroxyeicosatetraenoic acids--novel perioperative markers of early post-transplant allograft function?

Authors:  Barbara Dolegowska; Wojciech Blogowski; Krzysztof Safranow; Leszek Domanski; Katarzyna Jakubowska; Maria Olszewska
Journal:  Nephrol Dial Transplant       Date:  2010-06-08       Impact factor: 5.992

2.  Immobilization of rolling NK cells on platelet-borne P-selectin under flow by proinflammatory stimuli, interleukin-12, and leukotriene B4.

Authors:  S Sheikh; R S Parhar; R Bakheet; S Saleh; K Collison; F Al-Mohanna
Journal:  J Leukoc Biol       Date:  2004-06-03       Impact factor: 4.962

3.  Arachidonate lipoxygenase products and renal allograft rejection in dogs.

Authors:  M J Mangino; C B Anderson; K Deschryver; J Turk
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

4.  Gene expression of 5-, 12-, and 15-lipoxygenases and leukotriene receptors along the rat nephron.

Authors:  Stephan W Reinhold; Helga Vitzthum; Thomas Filbeck; Konrad Wolf; Christos Lattas; Günter A J Riegger; Armin Kurtz; Bernhard K Krämer
Journal:  Am J Physiol Renal Physiol       Date:  2005-10-11

5.  The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection.

Authors:  Bruce D Levy; Qing-yin Zhang; Caroline Bonnans; Valeria Primo; John J Reilly; David L Perkins; Yurong Liang; M Amin Arnaout; Boris Nikolic; Charles N Serhan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-09-24       Impact factor: 4.006

6.  In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils.

Authors:  K Fogh; T Herlin; K Kragballe
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

Review 7.  Conventional markers of kidney function.

Authors:  Sean M Bagshaw; R T Noel Gibney
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

8.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

9.  Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures.

Authors:  Anquan Liu; Hans-Erik Claesson; Yilmaz Mahshid; George Klein; Eva Klein
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

10.  Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension.

Authors:  Harpreet Singh; Jennifer Cheng; Huan Deng; Rowena Kemp; Tsuneo Ishizuka; Alberto Nasjletti; Michal Laniado Schwartzman
Journal:  Hypertension       Date:  2007-06-04       Impact factor: 10.190

View more
  5 in total

Review 1.  Glomerular Biomechanical Stress and Lipid Mediators during Cellular Changes Leading to Chronic Kidney Disease.

Authors:  Mukut Sharma; Vikas Singh; Ram Sharma; Arnav Koul; Ellen T McCarthy; Virginia J Savin; Trupti Joshi; Tarak Srivastava
Journal:  Biomedicines       Date:  2022-02-09

2.  Urinary leukotriene E4 is associated with renal function but not with endothelial function in type 2 diabetes.

Authors:  Arnar Rafnsson; Magnus Bäck
Journal:  Dis Markers       Date:  2013-10-02       Impact factor: 3.434

Review 3.  Leukotrienes and kidney diseases.

Authors:  Menachem Rubinstein; Efrat Dvash
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-01       Impact factor: 2.894

4.  Effect of renal replacement therapy on selected arachidonic acid derivatives concentration.

Authors:  Elżbieta Cecerska-Heryć; Rafał Heryć; Magda Wiśniewska; Natalia Serwin; Bartłomiej Grygorcewicz; Barbara Dołęgowska
Journal:  BMC Nephrol       Date:  2020-09-11       Impact factor: 2.388

5.  Xanthine oxidoreductase activity in platelet-poor and rich plasma as a oxidative stress indicator in patients required renal replacement therapy.

Authors:  Elżbieta Cecerska-Heryć; Rafał Heryć; Grażyna Dutkiewicz; Anna Michalczyk; Bartłomiej Grygorcewicz; Natalia Serwin; Sylwia Napiontek-Balińska; Barbara Dołęgowska
Journal:  BMC Nephrol       Date:  2022-01-18       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.